Has John Henry, MD received payments from drug or device companies?

Yes. Drug and device makers reported $81,630 in general payments to John Henry, MD across 853 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Henry, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Henry, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Henry, MD

Cardiovascular Disease · Omaha, NENPI 1831157213

Payments from drug & device makers

$81,630in general payments, 2019–2025

Across 853 payments — averaging $95.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$66K
Novartis$2K
Amryt Pharma Holdings Ltd$2K
E.r. Squibb & Sons, L.L.C.$1K
Chiesi USA, Inc.$1K
AstraZeneca$1K
plus $9K from 43 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	212	$66,123
Novartis	154	$1,757
Amryt Pharma Holdings Ltd	12	$1,608
E.r. Squibb & Sons, L.L.C.	56	$1,453
Chiesi USA, Inc.	7	$1,148
AstraZeneca	31	$1,026
Pfizer	58	$985
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	39	$888
Boehringer Ingelheim	42	$833
Johnson & Johnson	30	$610
Boston Scientific	12	$585
Sanofi-aventis U.S. LLC	28	$506
Bayer	20	$505
Merck	25	$484
Bridgebio Pharma, Inc.	11	$457
Actelion Pharmaceuticals US, Inc.	16	$429
Scpharmaceuticals Inc.	6	$325
Esperion Therapeutics, Inc.	13	$221
Heartflow, Inc.	2	$166
Edwards Lifesciences	9	$166
Alnylam Pharmaceuticals Inc.	8	$160
Amarin Pharma, Inc.	9	$156
United Therapeutics Corporation	6	$137
Regeneron Healthcare Solutions, Inc.	7	$122
GSK	3	$69
Gilead	4	$61
Kiniksa Pharmaceuticals, Ltd.	3	$55
Jazz Pharmaceuticals Inc.	2	$50
Lexicon Pharmaceuticals, Inc.	3	$47
Verona Pharma, Inc.	2	$43
Daiichi Sankyo Inc.	2	$39
Lantheus Medical Imaging, Inc.	2	$38
Inspire Medical Systems, Inc.	1	$35
Abbott	2	$32
Portola Pharmaceuticals, LLC	2	$32
Sanofi	1	$27
Grifols USA, LLC	1	$26
Kiniksa Pharmaceuticals International, PLC	1	$25
Pacira Pharmaceuticals Incorporated	1	$25
Abiomed	1	$24
Harmony Biosciences LLC	1	$22
Novo Nordisk	1	$20
Altathera Pharmaceuticals LLC	1	$20
Zimmer Biomet	1	$20
Vifor Pharma, Inc.	1	$15
Azurity Pharmaceuticals, Inc.	1	$15
Paratek Pharmaceuticals, Inc.	1	$14
Janssen Scientific Affairs, LLC	1	$14
Arbor Pharmaceuticals, Inc.	1	$12

How this compares

$81,630 in reported general payments places this provider in the 85th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska →

Medicare billing

Part B allowed, 2024

$396,351

Medicare patients

1,299

Services billed

4,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Omaha

Ronald ZoltyOmaha$6.3M
Jeffrey CarstensOmaha$299K
Joseph ThibodeauOmaha$251K
Edward OlearyOmaha$104K
Michael PetersOmaha$90K
Amjad KabachOmaha$75K
Thomas PorterOmaha$64K
Stanislaw SojkaOmaha$60K
Qais RadaidehOmaha$50K
Mark HolmbergOmaha$31K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →